|
Revenue from operations increased 22.15%YoY to Rs 586.12 crore in Q3 FY24, driven by market share gains, new launches, the addition of new customers, an increase in our share with existing customers, and incremental contributions from the acquired Teva facility.
Profit before tax jumped 42.23% to Rs 112.65 crore in Q3 FY24 as compared with Rs 79.20 crore in Q3 FY23.
In Q3 FY24, EBITDA was at Rs 133 crore as compared with Rs 76.6 crore in Q3 FY23, registering the growth of 73.56%. EBITDA margin improved by 672 bps to 22.70% in Q3 FY24 as against 15.97% in Q3 FY23.
During the quarter, US & North America were at Rs 257.5 crore (up 18.7% YoY) while UK and Europe stood at Rs 251 crore (up 34.4% YoY).
However, Australia and New Zealand business came in at Rs 48.6 crore (down 2.2% YoY) in Q3 FY24.
Rest of world (ROW) business grew by 9.8% YoY to Rs 29.1 crore during the period under review.
Mark Saldanha, managing director, Marksans Pharma, said, “We are thrilled to announce that we have delivered another quarter demonstrating robust performance. Our highest quarterly sales reached ~INR 586 crore. Positive momentum was observed in all our major regions. The US market grew by around 16% QoQ, mostly as a result of new product launches and the strengthening of our OTC portfolio. Our efforts toward building capabilities and capacity for the acquired Teva Pharma manufacturing facility are on track and we have also started filing DMF for backward integration. Looking ahead, we are optimistic about our strategic initiatives which will drive our future growth and sustainable long-term shareholder value.”
Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.
|